초록

The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.

대표청구항 ▼

1. A method for treating a subject with non-small cell lung cancer comprising: (a) selecting for treatment a subject having non-small cell lung cancer, wherein the subject has been HLA-typed and does not have an HLA haplotype selected from DQB1-02 and CWO7; and(b) administering to that subject, for

1. A method for treating a subject with non-small cell lung cancer comprising: (a) selecting for treatment a subject having non-small cell lung cancer, wherein the subject has been HLA-typed and does not have an HLA haplotype selected from DQB1-02 and CWO7; and(b) administering to that subject, for a period of time, a MUC-1-based formulation, wherein the formulation comprises: (i) a liposome; and(ii) at least one polypeptide comprising the amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO. 1 and the amino acid sequence of SEQ ID NO. 2. 2. The method of claim 1, wherein the formulation further comprises at least one adjuvant. 3. The method of claim 2, wherein the adjuvant is selected from the group consisting of lipid A, muramyl dipeptide, alum, a cytokine, and a combination thereof. 4. The method of claim 3, wherein the lipid A is monophosphoryl lipid A or a synthetic lipid A. 5. The method of claim 4, wherein the cytokine is interleukin-2. 6. The method of claim 1, further comprising a step (c) evaluating the treated subject wherein the evaluation is performed: (i) before the period of time of step (b);(ii) during the period of time of step (b);(iii) after the period of time of step (b); or(iv) a combination thereof. 7. The method of claim 6, wherein evaluating the treated subject comprises measuring an immune reaction in the treated subject. 8. The method of claim 7, wherein measuring the immune reaction in the treated subject comprises measuring a T-cell proliferation. 9. The method of claim 6, wherein evaluating the treated subject comprises determining at least one of: (a) tumor size, (b) tumor location, (c) nodal stage, (d) growth rate of the non-small cell lung cancer, (e) survival rate of the subject, (f) changes in the subject's lung cancer symptoms, (g) or changes in the subject's quality of life. 10. The method of claim 1, wherein the subject is diagnosed as having stage IIIB locoregional, stage IIIB malignant pleural effusion, or stage IV non-small cell lung cancer. 11. The method of claim 1, wherein the formulation is a BLP25 liposome vaccine comprising: (a) a MUC-1 peptide comprising the sequence of SEQ ID NOs: 1 or 2;(b) one or more adjuvants, and(c) one or more additional liposomal lipids. 12. The method of claim 11, wherein the BLP25 liposome vaccine is provided in a kit. 13. The method of claim 1, wherein the step of administering is by injection, aerosol, nasal, vaginal, rectal, buccal, ocular, local, topical, intracisternal, intraperitoneal, or oral delivery, and wherein the injection is an intramuscular, intravenous, subcutaneous, intranodal, intratumoral, intraperitoneal, or intradermal injection. 14. The method of claim 1, wherein the period of time is selected from the group consisting of at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, at least about 16 weeks, at least about 17 weeks, at least about 18 weeks, at least about 19 weeks, at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 60 weeks, at least about 68 weeks, at least about 72 weeks, at least about 80 weeks, at least about 88 weeks, at least about 96 weeks, and at least about 104 weeks. 15. The method of claim 1, wherein the individual is treated with cyclophosphamide prior to (b). 16. A method for improving or maintaining the quality of life of a subject diagnosed with non-small cell lung cancer, comprising: (a) selecting for treatment a subject having non-small cell lung cancer, wherein the subject has been HLA-typed and does not have an HLA haplotype selected from DQB1-02 and CWO7; and(b) administering to a subject diagnosed with non-small cell lung cancer a BLP25 liposome vaccine for a period of time, wherein the BLP25 liposome vaccine comprises:(a) a MUC-1 peptide comprising the sequence of SEQ ID NOs: 1 or 2;(b) one or more adjuvants; and(c) one or more additional liposomal lipids. 17. The method of claim 16, further comprising calculating a combined score of the subject's physical well-being, functional well-being, and lung cancer symptoms before, during, and after the period of time wherein the subject had been diagnosed with non-small cell lung cancer. 18. The method of claim 16, wherein the period of time is at least about 6 months, at least about 12 months, at least about 18 months, at least about 24 months, or longer than 24 months. 19. The method of claim 11, wherein the amount of MUC-1 peptide is about 300 μg. 20. The method of claim 11, wherein the adjuvant is lipid A. 21. The method of claim 20, wherein the amount of lipid A is about 150 μg. 22. The method of claim 11, wherein the amount of additional liposomal lipids is about 15 mg. 23. The method of claim 11, wherein the MUC-1 peptide comprises the sequence depicted in SEQ ID NO: 1. 24. The method of claim 11, wherein the MUC-1 peptide comprises the sequence depicted in SEQ ID NO: 2. 25. The method of claim 23, wherein the MUC-1 peptide is lipidated. 26. The method of claim 11, wherein the amount of MUC-1 peptide is about 1000 μg. 27. The method of claim 20, wherein the amount of lipid A is about 500 μg. 28. The method of claim 11, wherein the amount of additional liposomal lipids is about 50 mg.